Physician profile
Katherine Clore
NPI 1578572855
$4,032.66
in general payments reported to CMS, 2019-2025
9 companies · $474 in 2025
The $474 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $122 · 2021: $374 · 2022: $267 · 2023: $300 · 2024: $318 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Food and Beverage | $192.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,445.66 | 2019-2025 | Air Optix |
| Coopervision INC. | $1,421.27 | 2019-2025 | Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $787.77 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $137.35 | 2019-2021 | |
| Glaukos Corporation | $93.84 | 2025 | Photrexa Viscous and Photrexa |
| Harrow Eye, LLC | $80.52 | 2025 | Vevye |
| Biotissue Holdings INC. | $35.02 | 2022-2024 | |
| Shire North American Group INC | $18.51 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Clore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.